Skip to content

Clarify Pharma PLC - Notice of Annual General Meeting

Announcement provided by

Clarify Pharma PLC · PSYC

13/06/2023 15:51

Clarify Pharma PLC - Notice of Annual General Meeting
RNS Number : 5956C
Clarify Pharma PLC
13 June 2023

13 June 2023


Clarify Pharma PLC

("Clarify Pharma" or "the Company")


Notice of Annual General Meeting


Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, announces that it will hold its Annual General Meeting ('AGM') on Wednesday 5 July 2023 at 11 am BST, at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR.


Further details on the arrangement for this year's AGM are set out in the Notice of AGM, which together with the Form of Proxy, have been posted to shareholders today. The Notice of AGM will shortly also be available on the Company's website.


For further information, please visit or contact:

Clarify Pharma

Jon Bixby

Executive Chairman


via First Sentinel

First Sentinel

Corporate Adviser

Brian Stockbridge

+44 7876 888 011


About Clarify Pharma PLC:


Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

PSYC announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal